Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Net Cash Flow (2022 - 2025)

Atara Biotherapeutics' Net Cash Flow history spans 4 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 112.79% year-over-year to $2.7 million; the TTM value through Dec 2025 reached -$16.7 million, down 1958.45%, while the annual FY2025 figure was -$16.7 million, 1958.45% down from the prior year.
  • Net Cash Flow reached $2.7 million in Q4 2025 per ATRA's latest filing, up from -$11.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $26.6 million in Q4 2022 to a low of -$44.2 million in Q1 2023.
  • Average Net Cash Flow over 4 years is -$6.2 million, with a median of -$4.1 million recorded in 2022.
  • The largest YoY upside for Net Cash Flow was 438.95% in 2023 against a maximum downside of 890.39% in 2023.
  • A 4-year view of Net Cash Flow shows it stood at $26.6 million in 2022, then tumbled by 246.27% to -$38.9 million in 2023, then soared by 45.0% to -$21.4 million in 2024, then skyrocketed by 112.79% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Net Cash Flow are $2.7 million (Q4 2025), -$11.2 million (Q3 2025), and $2.9 million (Q2 2025).